Gland Pharma Limited has scheduled a series of meetings with analysts and institutional investors between June 9 and June 11, 2026, to provide updates on its operations and performance. The company will engage in one-on-one discussions with Haitong Securities, ICICI Securities, Midas Research, and Sohum Asset during this period.

The meetings are being conducted pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule includes sessions with Haitong Securities and a Non-Deal Roadshow (NDR) arranged by ICICI Securities on June 9, followed by Midas Research on June 10 and Sohum Asset on June 11.

The following table outlines the confirmed schedule for the meetings:

The company noted that the schedule is subject to change due to exigencies on the part of the investors, analysts, or the company itself. Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, signed the intimation on June 4, 2026.

Gland Pharma Limited has updated its schedule for meetings with analysts and institutional investors in June 2026. The company added new sessions with BofA and Emkay Global for June 04, 2026, supplementing previously announced interactions with Carnelian Asset Management and ICICI Securities later in the month.

The updated schedule includes a group meeting arranged by BofA and a one-on-one session with Emkay Global. These additions follow the earlier disclosed plan to host Carnelian Asset Management for a one-on-one meeting and participate in the ICICI Securities India Investor Conference 2026.

The company noted that the schedule remains subject to change due to exigencies on the part of investors, analysts, or the company.

The following table outlines the confirmed schedule:

Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, signed the intimation on May 29, 2026.